Success Stories

New and Innovative Study Technique for Osteosarcoma Metastasis

New and Innovative Study Technique for Osteosarcoma Metastasis

Osteosarcoma (OS) is a type of cancer that begins in the cells that form bones, and mainly affects teenagers and young adults. In metastatic osteosarcoma, the cancer spreads from the primary bone site to another location, most often the lungs. It can also spread to other bones, the brain or other organs. Currently there are no curative treatments for metastatic osteosarcoma. We urgently need to develop new therapies. To better understand a disease, it is common for tumor research studies to use orthotopic implantation. This method grafts tumor tissue where the disease begins in a mouse model. For osteosarcoma studies that would be in a bone allowing researchers to examine cancer progression more accurately and identify potential drug combinations more reliably. Rally-funded researcher Lindsay Jones Talbot, MD, is a pediatric surgeon, researcher, and instructor at St. Jude Children’s...

read more
INSTRuCT Database for Rhabdomyosarcoma Impact

INSTRuCT Database for Rhabdomyosarcoma Impact

Rally is proud to be the initial funder for the creation of the INSTRuCT Database with a Consortium Grant to Dr. Sam Volchenboum of the Pediatric Cancer Data Commons (PCDC) at the University of Chicago. Recent advances in genomic medicine look promising in the study of rhabdomyosarcoma (RMS). RMS is a rare soft tissue malignancy primarily diagnosed before adolescence.   RMS studies are historically challenged, given that only approximately 350 patients are diagnosed with RMS each year in the United States and around 700 patients a year in Western Europe. It is challenging to conduct clinical trials of anticancer drugs for the treatment of RMS due to the rarity, its various subtypes and differences in gene mutations. As a solution, the International Soft-Tissue Sarcoma Database Consortium (INSTRuCT) was created through collaboration with the Children’s Oncology Group (COG) Soft-Tissue...

read more
New RNA Therapies for Glioblastoma from Small Phase 1 Study

New RNA Therapies for Glioblastoma from Small Phase 1 Study

Glioblastoma (GBM) in children and adults is a deadly brain tumor with a poor prognosis. Current treatment includes surgery to remove as much of the tumor as possible, followed by radiation and chemotherapy. Unfortunately, most patients still experience tumor growth despite the treatment and have a median survival of less than two years.  Immunotherapy has shown success in the treatment of other types of tumors, but that success has been elusive with malignant brain tumors, such as GBM. However, new ribonucleic acid (RNA) based immunotherapy is showing promise in treatment for GBM. Rally-funded researcher Elias Sayour, MD, PhD, and his team at the University of Florida recently published exciting discoveries focusing on the utilization of RNA dendritic cell (DC) vaccines and RNA nanoparticle therapies in the treatment of GBM. RNA-based therapies offer clear advantages over other...

read more
AML Treatment Developments

AML Treatment Developments

Rally Foundation for Childhood Cancer Research is excited to announce new developments in the treatment of childhood acute myeloid leukemia (AML) emerging from research in the Meshinchi laboratory at the Fred Hutchinson Cancer Research Center (Fred Hutch) in Seattle. Immunotherapy is a type of treatment that harnesses the immune system to kill cancer cells.  To avoid toxicity and unpleasant side effects of treatment, researchers search for molecules or a “target” on the surface of cancer cells that do not exist on normal cells, so only the targeted cancer cells are attacked by the immune system. Such immunotherapies, including Chimeric Antigen Receptor (CAR) T-cell immunotherapy, have been successful in the treatment of acute lymphoblastic leukemia (ALL). Identification of such targets for AML has been more challenging because many of the targets found on AML cancer cells are also...

read more
The New England Journal of Medicine

The New England Journal of Medicine

Chills ran up and down my arms when I opened the link that Rally-funded researcher Dr. Gregory Friedman sent. I was staring at the New England Journal of Medicine logo, an article about Dr. Friedman’s brain cancer research and an acknowledgement to Rally for our support. “As a young investigator in 2013, I received my first grant directly supporting my lab research from Rally. The support enabled us to obtain the critical preclinical data needed for FDA approval to conduct the first pediatric trial of the therapy in recurrent high-grade gliomas,” shared Dr. Friedman. This week Dr. Friedman’s research was published in the New England Journal of Medicine, one of the most prestigious—if not the most prestigious—medical journals in the world. I often say at Rally we like to fund early, aren’t afraid of outside the box ideas and as long as the research is making progress, we will stick with...

read more
How Rally’s Grant Helped Rally Researcher Dr. Michael Kinnaman: Part 2

How Rally’s Grant Helped Rally Researcher Dr. Michael Kinnaman: Part 2

Rally Researcher, Medical Advisory Board member and pediatric oncologist Dr. Michael Kinnaman is the recipient of Rally’s Postdoctoral and Clinical Research Fellow Grant and most recently was awarded a 2020 Young Investigator Grant. In part two of this two-part series, Dr. Kinnaman reveals how our grant has helped fund his research project on characterizing osteosarcoma tumor cells that are resistant to our current therapy with the end goal of discovering new treatment strategies that are specifically targeted towards these resistant tumor cells. Read part one here.   Dr. Kinnaman Seeks to Understand the Complexities of Osteosarcoma One of the first patients I saw as a fellow at MSK Kids, Memorial Sloan Kettering’s Pediatric program, was a 12-year-old boy with newly diagnosed osteosarcoma of his right thigh bone. Osteosarcoma is the most common malignant bone tumor in children and...

read more

$

Sign up for our emails!

Fill out my online form.

Recent Posts

Success Stories

New and Innovative Study Technique for Osteosarcoma Metastasis

New and Innovative Study Technique for Osteosarcoma Metastasis

Osteosarcoma (OS) is a type of cancer that begins in the cells that form bones, and mainly affects teenagers and young adults. In metastatic osteosarcoma, the cancer spreads from the primary bone site to another location, most often the lungs. It can also spread to other bones, the brain or other organs. Currently there are no curative treatments for metastatic osteosarcoma. We urgently need to develop new therapies. To better understand a disease, it is common for tumor research studies to...

read more
INSTRuCT Database for Rhabdomyosarcoma Impact

INSTRuCT Database for Rhabdomyosarcoma Impact

Rally is proud to be the initial funder for the creation of the INSTRuCT Database with a Consortium Grant to Dr. Sam Volchenboum of the Pediatric Cancer Data Commons (PCDC) at the University of Chicago. Recent advances in genomic medicine look promising in the study of rhabdomyosarcoma (RMS). RMS is a rare soft tissue malignancy primarily diagnosed before adolescence.   RMS studies are historically challenged, given that only approximately 350 patients are diagnosed with RMS each year in the...

read more
New RNA Therapies for Glioblastoma from Small Phase 1 Study

New RNA Therapies for Glioblastoma from Small Phase 1 Study

Glioblastoma (GBM) in children and adults is a deadly brain tumor with a poor prognosis. Current treatment includes surgery to remove as much of the tumor as possible, followed by radiation and chemotherapy. Unfortunately, most patients still experience tumor growth despite the treatment and have a median survival of less than two years.  Immunotherapy has shown success in the treatment of other types of tumors, but that success has been elusive with malignant brain tumors, such as GBM....

read more
AML Treatment Developments

AML Treatment Developments

Rally Foundation for Childhood Cancer Research is excited to announce new developments in the treatment of childhood acute myeloid leukemia (AML) emerging from research in the Meshinchi laboratory at the Fred Hutchinson Cancer Research Center (Fred Hutch) in Seattle. Immunotherapy is a type of treatment that harnesses the immune system to kill cancer cells.  To avoid toxicity and unpleasant side effects of treatment, researchers search for molecules or a “target” on the surface of cancer cells...

read more
The New England Journal of Medicine

The New England Journal of Medicine

Chills ran up and down my arms when I opened the link that Rally-funded researcher Dr. Gregory Friedman sent. I was staring at the New England Journal of Medicine logo, an article about Dr. Friedman’s brain cancer research and an acknowledgement to Rally for our support. “As a young investigator in 2013, I received my first grant directly supporting my lab research from Rally. The support enabled us to obtain the critical preclinical data needed for FDA approval to conduct the first pediatric...

read more
How Rally’s Grant Helped Rally Researcher Dr. Michael Kinnaman: Part 2

How Rally’s Grant Helped Rally Researcher Dr. Michael Kinnaman: Part 2

Rally Researcher, Medical Advisory Board member and pediatric oncologist Dr. Michael Kinnaman is the recipient of Rally’s Postdoctoral and Clinical Research Fellow Grant and most recently was awarded a 2020 Young Investigator Grant. In part two of this two-part series, Dr. Kinnaman reveals how our grant has helped fund his research project on characterizing osteosarcoma tumor cells that are resistant to our current therapy with the end goal of discovering new treatment strategies that are...

read more

$

Sign up for our emails!

Fill out my online form.

Recent Posts

Volunteers are the heart of Rally's mission!

 

Enter your email below to receive details about our volunteer opportunities.

Thank you for your interest in volunteering with Rally! You should receive an email shortly with additional details.

X